Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,036.52 USD
+9.97 (0.97%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $1,043.70 +7.18 (0.69%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Brokerage Reports
Regeneron Pharmaceuticals, Inc. [REGN]
Reports for Purchase
Showing records 521 - 540 ( 592 total )
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eylea Programs Continue to Expand; Buy on Recent Selloff
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2012 Results; Ante Up for Future Growth and on Today''s Weakness
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Zaltrap Approved in Europe; Nice Headline but Focus on Eylea and PCSK9
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eylea Wows Yet Again, Poised for Blockbuster Status
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Important PCSK9 Visibility; Deep Commitment from Sanofi
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q12 Results; EYLEA Guidance Upped Again; Target to $181
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eylea Approved in Japan for Wet AMD; Target to $170.
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY.
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Regeneron Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive CHMP Opinion for Eylea in the E.U. for Wet AMD
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J